At its R&D Day in London today, Gubra provided updates on obesity assets licensed to AbbVie and Boehringer Ingelheim, as well as highlighted its lead internal program UCN2

0:00-22:51

CEO Markus Rohrwild and CDMO Thomas Langenickel provide an update on the company's peptide based drug development side, as well as venture and CRO arms.

B-

BiotechTV - News

@biotechtvnews

#gubraprovidedupdates #obesityassetslicensed #leadinternalprogram #lifesciences

The Nile